Daiichi Sankyo Company (4568-TO)

QUOTE AND NEWS
The Hindu Business Line  May 26  Comment 
Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic version Olmesartan Medoxomil tablets, used in the treatment of high blood pressure.
The Hindu Business Line  May 17  Comment 
Jubilant Life Sciences has received approval from the US health regulator to market amlodipine and olmesartan medoxomil tablets, used to treat hypertension, in the American market. Jubilant Pharma...
The Hindu Business Line  Apr 26  Comment 
Healthcare player Zydus Cadila informed about receiving the final approval from the US drug regulator US Food and Drug Administration (USFDA) to market Olmesartan Medoxomil tablets in the US market.
The Hindu Business Line  Apr 25  Comment 
Healthcare player Zydus Cadila on Tuesday informed about receiving the final approval from the US Food and Drug Administration (USFDA) to market Olmesartan Medoxomil tablets in the US market. The ...
The Economic Times  Apr 17  Comment 
The Singh brothers said court orders are not applicable to Religare as it is not party to the Japanese drug maker’s case to recover Rs 3,500 crore from them as part of an arbitration award.
The Economic Times  Mar 29  Comment 
Daiichi seeks court nod to induct external auditor to inspect the financial details disclosed by former Ranbaxy owners in the $500-mn arbitration award case.
The Economic Times  Mar 20  Comment 
Daiichi’s counsel alleged that the Singhs made false statements in affidavits about unencumbered assets of RHC Holding, the holding company for the brothers.
The Economic Times  Feb 28  Comment 
Justice S Muralidhar has directed the brothers to file a reply to Daiichi's allegations before the next hearing of the case on March 6, when Daiichi's latest plea is to be heard.





You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki